Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
申请人:Wyeth
公开号:US20040167122A1
公开(公告)日:2004-08-26
The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
1
本发明提供了一种I式化合物及其在治疗与5-HT6受体相关或受其影响的疾病中的应用。
HETEROCYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
申请人:Bernotas Ronald Charles
公开号:US20090253711A1
公开(公告)日:2009-10-08
The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
本发明提供了一种I式化合物及其在治疗与或受5-HT6受体相关的疾病中的应用。
US7238696B2
申请人:——
公开号:US7238696B2
公开(公告)日:2007-07-03
US7560470B2
申请人:——
公开号:US7560470B2
公开(公告)日:2009-07-14
[EN] 1-SUBSTITUTED-3-(NAPHTHALEN-1-YLSULFONYL)-5-(PIPERAZIN-1-YL)-1H-INDAZOLE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS<br/>[FR] COMPOSÉS DE 1-3-(NAPHTHALÉN-1-YLSULFONYL)-5-(PIPÉRAZIN-1-YL)-1H-INDAZOLE SUBSTITUÉ EN TANT QUE LIGANDS DE 5-HYDROXYTRYPTAMINE-6
申请人:WYETH CORP
公开号:WO2009155399A1
公开(公告)日:2009-12-23
The disclosure is directed to compounds of Formula I, processes for their preparation, treatment of central nervous system (CNS) disorders and methods for the modulation of 5HT6 activity.